CSL (ASX:CSL) - CEO & Managing Director, Paul Perreault
CEO & Managing Director, Paul Perreault
Source: CSL Behring
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Biotech giant CSL (CSL) has closed its global commercialisation and licence agreement with uniQure for AMT-061
  • Mid last year, CSL agreed to acquire the exclusive global licence rights to commercialise AMT-061 from uniQure for $656 million
  • AMT-061 is uniQure’s novel gene therapy for the treatment of haemophilia B, a blood clotting disorder
  • One dose of AMT-061 has shown to increase Factor IX plasma levels which is a blood clotting protein lacking in people with haemophilia B
  • CSL has ended the day a slight 0.28 per cent in the red with shares trading at $276.89

Biotech giant CSL (CSL) has closed its global commercialisation and licence agreement with uniQure for AMT-061.

Mid last year, CSL agreed to acquire the exclusive global licence rights to commercialise AMT-061 from uniQure for $656 million.

AMT-061, or etranacogene dezaparvovec, is uniQure’s novel gene therapy for the treatment of haemophilia B (blood clotting).

It contains an AAV5 viral vector which has shown to be safe and well-tolerated in many clinical trials. AAV5 moderates gene transfer in an independent manner.

One dose of AMT-061 has shown to increase Factor IX plasma levels which is a naturally produced protein that forms blood clots.

Unfortunately, this protein is highly lacking in haemophilia B patients.

AMT-061 is currently undergoing phase three clinical trials.

“This agreement enables us to take forward a gene therapy, that, if approved, has the potential to transform the lives of haemophilia B patients,” CEO and Managing Director Paul Perreault said.

“Etranacogene dezaparvovec has the potential to be the first-ever gene therapy approved for haemophilia B and help CSL deliver on our ongoing commitment to improving the lives of those living with haemophilia B,” he added.

CSL has ended the day a slight 0.28 per cent in the red with shares trading at $276.89 in a $126.3 billion market cap.

CSL by the numbers
More From The Market Herald

" ACCC approves Woolworths (ASX:WOW) and MyDeal (ASX:MYD) acquisition

The ACCC is not opposed on the deal the MyDeal (ASX:MYD) takeover by Woolworths (ASX:WOW).
The Market Herald Video

" Insurance Australia (ASX:IAG) back to making profit in FY22

Insurance Australia (ASX:IAG) records a 181.3 per cent increase in net profits for the 2022 financial…

" Telstra (ASX:TLS) increases its dividend for the first time in seven years

Telstra (ASX:TLS) has increased its dividend for the first time in seven years despite posting a…
AMP (ASX:AMP) - CEO, Alexis George

" AMP (ASX:AMP) flags $1.1b in upcoming shareholder returns despite profit slip

AMP (ASX:AMP) announces a fall in half-yearly profits of almost 25 per cent to $117 million…